Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase-Dependent Manner.

Authors

• Lebaron C Agostini
• Aditi Jain
• Alison Shupp
• Avinoam Nevler
• Grace McCarthy
• Karen M Bussard
• Charles J Yeo
• Jonathan R Brody

Publication/Presentation Date

2-1-2021

Abstract

The DNA damage response (DDR) pathway sets the stage for tumorigenesis and provides both an opportunity for drug efficacy and resistance. Therapeutic approaches to target the DDR pathway include aiming to increase the efficacy of cytotoxic chemotherapies and synergistic drug strategies to enhance DNA damage, and hence cell death. Here, we report the first preclinical evaluation of a novel synergistic approach by using both genetic and small-molecule inhibition methods of silencing the DDR-related protein, poly (ADP-ribose) glycohydrolase (PARG), and the checkpoint kinase inhibitor, Wee1, in pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma cells

Volume

19

Issue

2

First Page

207

Last Page

214

ISSN

1557-3125

Published In/Presented At

Agostini, L. C., Jain, A., Shupp, A., Nevler, A., McCarthy, G., Bussard, K. M., Yeo, C. J., & Brody, J. R. (2021). Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase-Dependent Manner. Molecular cancer research : MCR, 19(2), 207–214. https://doi.org/10.1158/1541-7786.MCR-20-0708

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

33257507

Department(s)

Administration and Leadership

Document Type

Article